hBD-1 vs Cotadutide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Cotadutide |
|---|---|---|
| Category | Dental & Oral | Weight Management |
| Full Name | Human beta-defensin 1 | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 4490 Da | ~4,700 Da |
| Half-Life | minutes to hours | Approximately 24 hours |
| Amino Acids | 36 | 37 |
| Typical Dose | 1-10 µg/mL in experimental studies | 0.3-3 mg daily in clinical studies |
| Route | Topical/Intraoral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 18 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.